Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Ferah Comert Onder; Nermin Kahraman; Esen Bellur Atici; Ali Cagir; Hakan Kandemir; Gizem Tatar; Tugba Taskin Tok; Goknur Kara; Bekir Karliga; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat

doi:10.1021/acsptsci.1c00113

Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Ferah Comert Onder, Nermin Kahraman, Esen Bellur Atici, Ali Cagir, Hakan Kandemir, Gizem Tatar, Tugba Taskin Tok, Goknur Kara, Bekir Karliga, Serdar Durdagi, Mehmet Ay, Bulent Ozpolat

Experimental Therapeutics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

Original language	English (US)
Pages (from-to)	1247
Number of pages	1
Journal	ACS Pharmacology and Translational Science
Volume	4
Issue number	3
DOIs	https://doi.org/10.1021/acsptsci.1c00113
State	Published - Jun 11 2021

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1021/acsptsci.1c00113

Fingerprint

Dive into the research topics of 'Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)'. Together they form a unique fingerprint.

Cite this

Comert Onder, F., Kahraman, N., Bellur Atici, E., Cagir, A., Kandemir, H., Tatar, G., Taskin Tok, T., Kara, G., Karliga, B., Durdagi, S., Ay, M., & Ozpolat, B. (2021). Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). ACS Pharmacology and Translational Science, 4(3), 1247. https://doi.org/10.1021/acsptsci.1c00113

Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). / Comert Onder, Ferah; Kahraman, Nermin; Bellur Atici, Esen et al.
In: ACS Pharmacology and Translational Science, Vol. 4, No. 3, 11.06.2021, p. 1247.

Research output: Contribution to journal › Comment/debate › peer-review

Comert Onder, F, Kahraman, N, Bellur Atici, E, Cagir, A, Kandemir, H, Tatar, G, Taskin Tok, T, Kara, G, Karliga, B, Durdagi, S, Ay, M & Ozpolat, B 2021, 'Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)', ACS Pharmacology and Translational Science, vol. 4, no. 3, pp. 1247. https://doi.org/10.1021/acsptsci.1c00113

Comert Onder F, Kahraman N, Bellur Atici E, Cagir A, Kandemir H, Tatar G et al. Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). ACS Pharmacology and Translational Science. 2021 Jun 11;4(3):1247. doi: 10.1021/acsptsci.1c00113

@article{42dc804c3fd646f08db1554c569b0eab,

title = "Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)",

abstract = "The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.",

author = "{Comert Onder}, Ferah and Nermin Kahraman and {Bellur Atici}, Esen and Ali Cagir and Hakan Kandemir and Gizem Tatar and {Taskin Tok}, Tugba and Goknur Kara and Bekir Karliga and Serdar Durdagi and Mehmet Ay and Bulent Ozpolat",

note = "Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",

year = "2021",

month = jun,

day = "11",

doi = "10.1021/acsptsci.1c00113",

language = "English (US)",

volume = "4",

pages = "1247",

journal = "ACS Pharmacology and Translational Science",

issn = "2575-9108",

publisher = "American Chemical Society",

number = "3",

}

TY - JOUR

T1 - Erratum

T2 - Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

AU - Comert Onder, Ferah

AU - Kahraman, Nermin

AU - Bellur Atici, Esen

AU - Cagir, Ali

AU - Kandemir, Hakan

AU - Tatar, Gizem

AU - Taskin Tok, Tugba

AU - Kara, Goknur

AU - Karliga, Bekir

AU - Durdagi, Serdar

AU - Ay, Mehmet

AU - Ozpolat, Bulent

PY - 2021/6/11

Y1 - 2021/6/11

N2 - The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

AB - The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

UR - http://www.scopus.com/inward/record.url?scp=85106566787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106566787&partnerID=8YFLogxK

U2 - 10.1021/acsptsci.1c00113

DO - 10.1021/acsptsci.1c00113

M3 - Comment/debate

C2 - 34151214

AN - SCOPUS:85106566787

SN - 2575-9108

VL - 4

SP - 1247

JO - ACS Pharmacology and Translational Science

JF - ACS Pharmacology and Translational Science

IS - 3

ER -

Erratum: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this